Dipeptidyl peptidase-4 regulation of SDF-1/CXCR4 axis: Implications for cardiovascular disease

Frontiers in Immunology

Volumn 6, Issue SEP, 2015, Pages

  Zhong, Jixin ^a   Rajagopalan, Sanjay ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; Chemokine; CXCR4; Dipeptidyl peptidase 4; SDF 1

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; EOTAXIN; GRANULOCYTE COLONY STIMULATING FACTOR; INCRETIN; INTERLEUKIN 3; PARATHYROID HORMONE; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1;

ACUTE HEART INFARCTION; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL HOMING; CELL SURVIVAL; ENZYME ACTIVITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC CARDIOMYOPATHY; LYMPHOCYTOPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION;

EID: 84946560133     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00477     Document Type: Review

References (98)

1. Hopsu-Havu, VK, and Glenner, GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie (1966) 7:197-201. doi: 10.1007/BF00577838.
2. Mulvihill, EE, and Drucker, DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev (2014) 35:992-1019. doi:10.1210/er.2014-1035.
3. Zhong, J, Maiseyeu, A, Davis, SN, and Rajagopalan, S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res (2015) 116:1491-504. doi:10.1161/CIRCRESAHA.116.305665.
4. Duke-Cohan, JS, Morimoto, C, Rocker, JA, and Schlossman, SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol (1996) 156:1714-21.
5. Lambeir, AM, Díaz Pereira, JF, Chacón, P, Vermeulen, G, Heremans, K, Devreese, B, et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta (1997) 1340:215-26. doi:10.1016/S0167-4838(97)00045-9.
6. Andrieu, T, Thibault, V, Malet, I, Laporte, J, Bauvois, B, Agut, H, et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol (2003) 27:59-68. doi:10.1016/S1386-6532(02)00128-2.
7. Grondin, G, Hooper, NM, and LeBel, D. Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells. J Histochem Cytochem (1999) 47:489-98. doi:10.1177/002215549904700407.
8. Topham, NJ, and Hewitt, EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology (2009) 128:7-15. doi:10.1111/j.1365-2567.2009.03123.x.
9. Lamers, D, Famulla, S, Wronkowitz, N, Hartwig, S, Lehr, S, Ouwens, DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes (2011) 60:1917-25. doi:10.2337/db10-1707.
10. Kirino, Y, Sato, Y, Kamimoto, T, Kawazoe, K, and Minakuchi, K. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab (2011) 300:E372-9. doi:10.1152/ajpendo.00319.2010.
11. Mentzel, S, Dijkman, HB, Van Son, JP, Koene, RA, and Assmann, KJ. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem (1996) 44:445-61. doi:10.1177/44.5.8627002.
12. Zhong, J, Rao, X, Deiuliis, J, Braunstein, Z, Narula, V, Hazey, J, et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes (2013) 62:149-57. doi:10.2337/db12-0230.
13. Zhong, J, Rao, X, and Rajagopalan, S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis (2013) 226:305-14. doi:10.1016/j.atherosclerosis.2012.09.012.
14. Gorrell, MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (2005) 108:277-92. doi:10.1042/CS20040302.
15. Conarello, SL, Li, Z, Ronan, J, Roy, RS, Zhu, L, Jiang, G, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A (2003) 100:6825-30. doi:10.1073/pnas.0631828100.
16. Marguet, D, Baggio, L, Kobayashi, T, Bernard, AM, Pierres, M, Nielsen, PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A (2000) 97:6874-9. doi:10.1073/pnas.120069197.
17. Morimoto, C, and Schlossman, SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev (1998) 161:55-70. doi:10.1111/j.1600-065X.1998.tb01571.x.
18. Ohnuma, K, Takahashi, N, Yamochi, T, Hosono, O, Dang, NH, and Morimoto, C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci (2008) 13:2299-310. doi:10.2741/2844.
19. Shah, Z, Kampfrath, T, Deiuliis, JA, Zhong, J, Pineda, C, Ying, Z, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation (2011) 124:2338-49. doi:10.1161/CIRCULATIONAHA.111.041418.
20. Shah, Z, Pineda, C, Kampfrath, T, Maiseyeu, A, Ying, Z, Racoma, I, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol (2011) 55:2-9. doi:10.1016/j.vph.2011.03.001.
21. Lu, G, Hu, Y, Wang, Q, Qi, J, Gao, F, Li, Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 500:227-31. doi:10.1038/nature12328.
22. Kanasaki, K, Shi, S, Kanasaki, M, He, J, Nagai, T, Nakamura, Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes (2014) 63:2120-31. doi:10.2337/db13-1029.
23. Mega, C, Teixeira De Lemos, E, Vala, H, Fernandes, R, Oliveira, J, Mascarenhas-Melo, F, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res (2011) 2011:162092. doi:10.1155/2011/162092.
24. Sueyoshi, R, Woods Ignatoski, KM, Okawada, M, Hartmann, B, Holst, J, and Teitelbaum, DH. Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model. Am J Physiol Gastrointest Liver Physiol (2014) 307:G410-9. doi:10.1152/ajpgi.00363.2013.
25. Ben-Shlomo, S, Zvibel, I, Shnell, M, Shlomai, A, Chepurko, E, Halpern, Z, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol (2011) 54:1214-23. doi:10.1016/j.jhep.2010.09.032.
26. Firneisz, G, Varga, T, Lengyel, G, Fehér, J, Ghyczy, D, Wichmann, B, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One (2010) 5:e12226. doi:10.1371/journal.pone.0012226.
27. Iwata, S, Yamaguchi, N, Munakata, Y, Ikushima, H, Lee, JF, Hosono, O, et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol (1999) 11:417-26. doi:10.1093/intimm/11.3.417.
28. Struyf, S, Proost, P, Schols, D, De Clercq, E, Opdenakker, G, Lenaerts, JP, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol (1999) 162:4903-9.
29. Forssmann, U, Stoetzer, C, Stephan, M, Kruschinski, C, Skripuletz, T, Schade, J, et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol (2008) 181:1120-7. doi:10.4049/jimmunol.181.2.1120.
30. Godiska, R, Chantry, D, Raport, CJ, Sozzani, S, Allavena, P, Leviten, D, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med (1997) 185:1595-604. doi:10.1084/jem.185.9.1595.
31. Andrew, DP, Chang, MS, McNinch, J, Wathen, ST, Rihanek, M, Tseng, J, et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol (1998) 161:5027-38.
32. Proost, P, Struyf, S, Schols, D, Opdenakker, G, Sozzani, S, Allavena, P, et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem (1999) 274:3988-93. doi:10.1074/jbc.274.7.3988.
33. Proost, P, Schutyser, E, Menten, P, Struyf, S, Wuyts, A, Opdenakker, G, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood (2001) 98:3554-61. doi:10.1182/blood. V98.13.3554.
34. Kanki, S, Segers, VFM, Wu, W, Kakkar, R, Gannon, J, Sys, SU, et al. Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ Heart Fail (2011) 4:509-18. doi:10.1161/CIRCHEARTFAILURE.110.960302.
35. Broxmeyer, HE, Hoggatt, J, O'Leary, HA, Mantel, C, Chitteti, BR, Cooper, S, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med (2012) 18:1786-96. doi:10.1038/nm.2991.
36. Bromage, DI, Davidson, SM, and Yellon, DM. Stromal derived factor 1a: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther (2014) 143:305-15. doi:10.1016/j.pharmthera.2014.03.009.
37. Aiuti, A, Webb, IJ, Bleul, C, Springer, T, and Gutierrez-Ramos, JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med (1997) 185:111-20. doi:10.1084/jem.185.1.111.
38. Kondo, K, Shintani, S, Shibata, R, Murakami, H, Murakami, R, Imaizumi, M, et al. Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol (2009) 29:61-6. doi:10.1161/ATVBAHA.108.166496.
39. Zaruba, M-M, and Franz, W-M. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther (2010) 10:321-35. doi:10.1517/14712590903460286.
40. Ghadge, SK, Mühlstedt, S, Özcelik, C, and Bader, M. SDF-1a as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther (2011) 129:97-108. doi:10.1016/j.pharmthera.2010.09.011.
41. Kucia, M, Reca, R, Miekus, K, Wanzeck, J, Wojakowski, W, Janowska-Wieczorek, A, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells (2005) 23:879-94. doi:10.1634/stemcells.2004-0342.
42. Nagasawa, T, Nakajima, T, Tachibana, K, Iizasa, H, Bleul, CC, Yoshie, O, et al. Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S A (1996) 93:14726-9. doi:10.1073/pnas.93.25.14726.
43. Ratajczak, MZ, Zuba-Surma, E, Kucia, M, Reca, R, Wojakowski, W, and Ratajczak, J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia (2006) 20:1915-24. doi:10.1038/sj.leu.2404357.
44. Askari, AT, Unzek, S, Popovic, ZB, Goldman, CK, Forudi, F, Kiedrowski, M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 362:697-703. doi:10.1016/S0140-6736(03)14232-8.
45. Segret, A, Rücker-Martin, C, Pavoine, C, Flavigny, J, Deroubaix, E, Châtel, M-A, et al. Structural localization and expression of CXCL12 and CXCR4 in rat heart and isolated cardiac myocytes. J Histochem Cytochem (2007) 55:141-50. doi:10.1369/jhc.6A7050.2006.
46. McQuibban, GA, Butler, GS, Gong, JH, Bendall, L, Power, C, Clark-Lewis, I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem (2001) 276:43503-8. doi:10.1074/jbc. M107736200.
47. Rollins, BJ. Chemokines. Blood (1997) 90:909-28.
48. Nagasawa, T, Hirota, S, Tachibana, K, Takakura, N, Nishikawa, S, Kitamura, Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 382:635-8. doi:10.1038/382635a0.
49. Tachibana, K, Hirota, S, Iizasa, H, Yoshida, H, Kawabata, K, Kataoka, Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 393:591-4. doi:10.1038/31261.
50. Zou, YR, Kottmann, AH, Kuroda, M, Taniuchi, I, and Littman, DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 393:595-9. doi:10.1038/31269.
51. Hernandez, PA, Gorlin, RJ, Lukens, JN, Taniuchi, S, Bohinjec, J, Francois, F, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet (2003) 34:70-4. doi:10.1038/ng1149.
52. Tarnowski, M, Liu, R, Wysoczynski, M, Ratajczak, J, Kucia, M, and Ratajczak, MZ. CXCR7: a new SDF-1-binding receptor in contrast to normal CD34+ progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur J Haematol (2010) 85:472-83. doi:10.1111/j.1600-0609.2010.01531.x.
53. Liu, H, Liu, S, Li, Y, Wang, X, Xue, W, Ge, G, et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One (2012) 7:e34608. doi:10.1371/journal.pone.0034608.
54. Devine, SM, Vij, R, Rettig, M, Todt, L, McGlauchlen, K, Fisher, N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 112:990-8. doi:10.1182/blood-2007-12-130179.
55. Hess, DA, Bonde, J, Craft, TC, Wirthlin, L, Hohm, S, Lahey, R, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant (2007) 13:398-411. doi:10.1016/j.bbmt.2006.12.445.
56. Dar, A, Schajnovitz, A, Lapid, K, Kalinkovich, A, Itkin, T, Ludin, A, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia (2011) 25:1286-96. doi:10.1038/leu.2011.62.
57. Chiriac, A, Terzic, A, Park, S, Ikeda, Y, Faustino, R, and Nelson, TJ. SDF-1-enhanced cardiogenesis requires CXCR4 induction in pluripotent stem cells. J Cardiovasc Transl Res (2010) 3(6):674-82. doi:10.1007/s12265-010-9219-1.
58. Chiriac, A, Nelson, TJ, Faustino, RS, Behfar, A, and Terzic, A. Cardiogenic induction of pluripotent stem cells streamlined through a conserved SDF-1/VEGF/BMP2 integrated network. PLoS One (2010) 5(4):e9943. doi:10.1371/journal.pone.0009943.
59. Penn, MS, Pastore, J, Miller, T, and Aras, R. SDF-1 in myocardial repair. Gene Ther (2012) 19:583-7. doi:10.1038/gt.2012.32.
60. Peled, A, Kollet, O, Ponomaryov, T, Petit, I, Franitza, S, Grabovsky, V, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood (2000) 95(11):3289-96.
61. Deglurkar, I, Mal, N, Mills, WR, Popovic, ZB, McCarthy, P, Blackstone, EH, et al. Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther (2006) 17:1144-51. doi:10.1089/hum.2006.17.1144.
62. Sundararaman, S, Miller, TJ, Pastore, JM, Kiedrowski, M, Aras, R, and Penn, MS. Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure. Gene Ther (2011) 18:867-73. doi:10.1038/gt.2011.18.
63. Rodrigues, CO, Shehadeh, LA, Hoosien, M, Otero, V, Chopra, I, Tsinoremas, NF, et al. Heterogeneity in SDF-1 expression defines the vasculogenic potential of adult cardiac progenitor cells. PLoS One (2011) 6(8):e24013. doi:10.1371/journal.pone.0024013.
64. Christopherson, KW, Hangoc, G, Mantel, CR, and Broxmeyer, HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science (2004) 305:1000-3. doi:10.1126/science.1097071.
65. Christopherson, KW, Hangoc, G, and Broxmeyer, HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol (2002) 169:7000-8. doi:10.4049/jimmunol.169.12.7000.
66. Broxmeyer, HE, Hangoc, G, Cooper, S, Campbell, T, Ito, S, and Mantel, C. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci (2007) 1106:1-19. doi:10.1196/annals.1392.013.
67. Campbell, TB, Hangoc, G, Liu, Y, Pollok, K, and Broxmeyer, HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev (2007) 16:347-54. doi:10.1089/scd.2007.9995.
68. Christopherson, KW, Paganessi, LA, Napier, S, and Porecha, NK. CD26 inhibition on CD34+ or lineage-human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev (2007) 16:355-60. doi:10.1089/scd.2007.9996.
69. Kawai, T, Choi, U, Liu, P-C, Whiting-Theobald, NL, Linton, GF, and Malech, HL. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev (2007) 16:361-70. doi:10.1089/scd.2007.9997.
70. Jungraithmayr, W, De Meester, I, Matheeussen, V, Baerts, L, Arni, S, and Weder, W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemiareperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg (2012) 41:1166-73. doi:10.1093/ejcts/ezr180.
71. Liebler, JM, Lutzko, C, Banfalvi, A, Senadheera, D, Aghamohammadi, N, Crandall, ED, et al. Retention of human bone marrow-derived cells in murine lungs following bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2008) 295:L285-92. doi:10.1152/ajplung.00222.2007.
72. Christopherson, KW, Uralil, SE, Porecha, NK, Zabriskie, RC, Kidd, SM, and Ramin, SM. G-CSF-and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD38-human cord blood hematopoietic cells. Exp Hematol (2006) 34:1060-8. doi:10.1016/j.exphem.2006.03.012.
73. Asahara, T, Murohara, T, Sullivan, A, Silver, M, van der Zee, R, Li, T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275:964-7. doi:10.1126/science.275.5302.964.
74. Walter, DH, Rochwalsky, U, Reinhold, J, Seeger, F, Aicher, A, Urbich, C, et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol (2007) 27:275-82. doi:10.1161/01.ATV.0000254669.12675.70.
75. Foubert, P, Silvestre, JS, Souttou, B, Barateau, V, Martin, C, Ebrahimian, TG, et al. PSGL-1-mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cells. J Clin Invest (2007) 117:1527-37. doi:10.1172/JCI28338.
76. Yamaguchi, J, Kusano, KF, Masuo, O, Kawamoto, A, Silver, M, Murasawa, S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation (2003) 107:1322-8. doi:10.1161/01.CIR.0000055313.77510.22.
77. Shen, L, Gao, Y, Qian, J, Sun, A, and Ge, J. A novel mechanism for endothelial progenitor cells homing: the SDF-1/CXCR4-Rac pathway may regulate endothelial progenitor cells homing through cellular polarization. Med Hypotheses (2011) 76:256-8. doi:10.1016/j.mehy.2010.10.014.
78. Shao, H, Tan, Y, Eton, D, Yang, Z, Uberti, MG, Li, S, et al. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells (2008) 26:1376-84. doi:10.1634/stemcells.2007-0785.
79. De Falco, E, Porcelli, D, Torella, AR, Straino, S, Iachininoto, MG, Orlandi, A, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood (2004) 104:3472-82. doi:10.1182/blood-2003-12-4423.
80. Youn, SW, Lee, SW, Lee, J, Jeong, HK, Suh, JW, Yoon, CH, et al. COMP-Ang1 stimulates HIF-1a-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment. Blood (2011) 117:4376-86. doi:10.1182/blood-2010-07-295964.
81. Zemani, F, Silvestre, JS, Fauvel-Lafeve, F, Bruel, A, Vilar, J, Bieche, I, et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol (2008) 28:644-50. doi:10.1161/ATVBAHA.107.160044.
82. Segal, MS, Shah, R, Afzal, A, Perrault, CM, Chang, K, Schuler, A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes (2006) 55:102-9. doi:10.2337/diabetes.55.01.06.db05-0803.
83. Shih, C-M, Chen, Y-H, Yi, W-L, Tsao, N-W, Wu, S-C, Kao, Y-T, et al. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Curr Med Chem (2014) 21(17):2012-22. doi:10.2174/09298673113206660273.
84. Zhang, M, Mal, N, Kiedrowski, M, Chacko, M, Askari, AT, Popovic, ZB, et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J (2007) 21:3197-207. doi:10.1096/fj.06-6558com.
85. Dong, F, Harvey, J, Finan, A, Weber, K, Agarwal, U, and Penn, MS. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation (2012) 126:314-24. doi:10.1161/CIRCULATIONAHA.111.082453.
86. Zaruba, M-M, Theiss, HD, Vallaster, M, Mehl, U, Brunner, S, David, R, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell (2009) 4:313-23. doi:10.1016/j.stem.2009.02.013.
87. Zaruba, MM, Zhu, W, Soonpaa, MH, Reuter, S, Franz, WM, and Field, LJ. Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes. Eur Heart J (2012) 33:129-37. doi:10.1093/eurheartj/ehr302.
88. Zhang, D, Huang, W, Dai, B, Zhao, T, Ashraf, A, Millard, RW, et al. Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am J Physiol Heart Circ Physiol (2010) 299:H1339-47. doi:10.1152/ajpheart.00592.2010.
89. Segers, VFM, Revin, V, Wu, W, Qiu, H, Yan, Z, Lee, RT, et al. Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation (2011) 123:1306-15. doi:10.1161/CIRCULATIONAHA.110.991786.
90. Zaruba, M-M, Hiergeist, L, Mechea, A, Kozlik-Feldmann, R, Theisen, D, Netz, H, et al. First treatment of a child suffering from severe ischemic cardiomyopathy with G-CSF and sitagliptin. Int J Cardiol (2013) 170:e41-2. doi:10.1016/j.ijcard.2013.10.073.
91. Huber, BC, Brunner, S, Segeth, A, Nathan, P, Fischer, R, Zaruba, MM, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res (2011) 90:529-37. doi:10.1093/cvr/cvr014.
92. Haverslag, RT, de Groot, D, Grundmann, S, Meder, B, Goumans, M-J, Pasterkamp, G, et al. CD26 inhibition enhances perfusion recovery in ApoE-/-mice. Curr Vasc Pharmacol (2013) 11:21-8. doi:10.2174/157016113804547566.
93. Penn, MS, Mendelsohn, FO, Schaer, GL, Sherman, W, Farr, M, Pastore, J, et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res (2013) 112:816-25. doi:10.1161/CIRCRESAHA.111.300440.
94. Chung, ES, Miller, L, Patel, AN, Anderson, RD, Mendelsohn, FO, Traverse, J, et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized phase II trial. Eur Heart J (2015) 36(33):2228-38. doi:10.1093/eurheartj/ehv254.
95. Pyo, RT, Sui, J, Dhume, A, Palomeque, J, Blaxall, BC, Diaz, G, et al. CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol (2006) 41:834-44. doi:10.1016/j.yjmcc.2006.08.008.
96. Scirica, BM, Bhatt, DL, Braunwald, E, Steg, PG, Davidson, J, Hirshberg, B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 369:1317-26. doi:10.1056/NEJMoa1307684.
97. White, WB, Cannon, CP, Heller, SR, Nissen, SE, Bergenstal, RM, Bakris, GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 369:1327-35. doi:10.1056/NEJMoa1305889.
98. Green, JB, Bethel, MA, Armstrong, PW, Buse, JB, Engel, SS, Garg, J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015) 373(3):232-42. doi:10.1056/NEJMoa1501352.